Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Inc SRPT
News
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug
Sarepta Shares Soar 37% Following Expanded Approval for Elevidys
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Outperforming ETF manager names a potential '50-bagger' in the stock market
Outperforming ETF manager names a potential -2-
Outperforming ETF manager names a potential '50-bagger' in the stock market
Outperforming ETF manager names a potential -2-
Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal
Sarepta Therapeutics to Request Expansion of Elevidys to All Age Groups Following Study Results
United States